AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 222 min read$CLDX

Celldex's Barzolvolimab Meets Phase 3 Goals In Chronic Hives Studies; Stock Down

Celldex (CLDX) reported positive Phase 3 results for Barzolvolimab in chronic hives studies, meeting primary and secondary endpoints. The drug showed rapid and sustained efficacy, with plans to submit a Biologics License Application in 2027. CLDX stock is down 16.57% to $31.67.

Original reporting
rttnews.com
Published Sep 22, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 5:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CLDX
Bullish
high confidence
Mentioned
$CLDX
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CLDXBullishMed
01

Why it matters

Positive Phase 3 results are a key value inflection point for CLDX, likely to attract analyst upgrades and institutional buying.

02

Market read

First‑report of pivotal trial success; material for traders targeting biotech catalysts.

03

What to watch

Regulatory timeline (BLA filing in 2027) and potential need for larger Phase 3 confirmatory study.

Relevance 9/10Novelty 9/10Timing: today

Background

Celldex (CLDX) is a clinical‑stage biotech focused on immunology. The company plans a BLA filing in 2027.

Company-level read

Ticker impact

$CLDXBullishHigh confidence
Context

Celldex reported positive Phase 3 trial results for Barzolvolimab in chronic spontaneous urticaria.

Expected impact

Potential upside of 10‑15% over the next 2‑4 weeks if data is confirmed by analysts.

Evidence & confidence

Phase 3 success is a material catalyst for a biotech; the stock is already down on the news, suggesting a short‑term oversell that may reverse.

Market effects

Sector

Strengthens the chronic hives therapeutic space and may boost peer biotech valuations.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

The data may not translate into commercial success; reimbursement and competition could limit upside.

Key entities

  • company
    Celldex Therapeutics

    Biotech developing Barzolvolimab for chronic spontaneous urticaria.

Read at source← All news

Related articles

SEP 23
$CLDXMedAI 8/10

Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings

Guggenheim's biotech rankings place Celldex Therapeutics (CLDX) at the top due to positive Phase III trial results for barzovolimab in treating chronic spontaneous urticaria. The drug showed strong efficacy and a low rate of severe anaphylaxis. CLDX recently discontinued a prurigo nodularis study after it failed to meet endpoints. Analysts have mixed price target adjustments.

investing.com2 min
SEP 23
$CLDXHighAI 9/10

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

Celldex Therapeutics (CLDX) reported positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria, meeting all primary and secondary endpoints. The drug showed significant efficacy, with a majority of patients achieving complete symptom relief. However, the company faces high R&D costs and a 2027 expected BLA filing. CLDX has $717.6M in cash and a pipeline of other studies, but a recent Phase 2 failure in prurigo nodularis highlights risks.

insidermonkey.com3 min
SEP 22
$CLDXHighAI 8/10

Why is Celldex Therapeutics stock sliding today?

Celldex Therapeutics (CLDX) stock fell 10.4% after Phase 3 trial results for barzolvolimab met primary and secondary endpoints but showed smaller efficacy gains than Phase 2. Analysts maintained positive ratings and price targets. The broader market had minimal impact, highlighting the company-specific move.

investing.com2 min
SEP 22
$CLDXMedAI 9/10

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

Celldex Therapeutics (CLDX) stock fell 11% despite positive Phase 3 trial results for Barzolvolimab, its treatment for chronic spontaneous urticaria. H.C. Wainwright raised its price target to $64, citing nearly 90% upside potential. The studies met primary and secondary endpoints, but safety concerns, including two cases of probable Grade 4 anaphylaxis, led to the initial sell-off. Celldex plans to file for FDA approval in 2027.

stocktwits.com2 min
SEP 22
$CLDXMedAI 8/10

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (CLDX) reported positive Phase 3 trial results for barzolvolimab in treating chronic spontaneous urticaria (CSU). Both studies met primary and secondary endpoints, showing significant symptom improvement. The treatment also showed sustained efficacy and a favorable safety profile. CLDX plans to submit a Biologics License Application to the FDA in 2027. Shares initially rose but later fell 12.51% to $36.65.

benzinga.com2 min